Literature DB >> 6705446

Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways.

J O Miners, J Attwood, D J Birkett.   

Abstract

Acetaminophen metabolism and clearance after a single 1 gm oral dose of the drug was investigated in 12 healthy men, six of whom were cigarette smokers, and in six men who were receiving anticonvulsant drugs for epilepsy. The 12 healthy subjects were studied before and after 1 wk of pretreatment with cimetidine (1 gm/day) or sulfinpyrazone (800 mg/day). There was no significant difference in acetaminophen clearance (ClAP) between nonsmokers and smokers; cimetidine pretreatment had no effect on ClAP. Neither cigarette smoking nor cimetidine pretreatment had a significant effect on any of the metabolic pathways of acetaminophen. In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg). In both cases the increase in ClAP was a result of induction of acetaminophen glucuronidation and oxidation; clearance of the glucuronic acid conjugate was 26% and 59% greater and clearance of the glutathione-derived conjugates (reflecting the activity of the oxidative pathway) was 43% and 60% greater in the groups given sulfinpyrazone and anticonvulsants, respectively.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705446     DOI: 10.1038/clpt.1984.64

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  The Effect of 4-Methylpyrazole on Oxidative Metabolism of Acetaminophen in Human Volunteers.

Authors:  A Min Kang; Angela Padilla-Jones; Erik S Fisher; Jephte Y Akakpo; Hartmut Jaeschke; Barry H Rumack; Richard D Gerkin; Steven C Curry
Journal:  J Med Toxicol       Date:  2019-11-25

Review 2.  Paracetamol: new vistas of an old drug.

Authors:  Alfio Bertolini; Anna Ferrari; Alessandra Ottani; Simona Guerzoni; Raffaella Tacchi; Sheila Leone
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

3.  [Not Available].

Authors:  K Menges
Journal:  Schmerz       Date:  1987-09       Impact factor: 1.107

Review 4.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 6.  Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.

Authors:  J O Miners
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

7.  Interaction of metoprolol with lorazepam and bromazepam.

Authors:  A K Scott; G A Cameron; G M Hawksworth
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 8.  The role of conjugation reactions in detoxication.

Authors:  K W Bock; W Lilienblum; G Fischer; G Schirmer; B S Bock-Henning
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

9.  Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking.

Authors:  K W Bock; J Wiltfang; R Blume; D Ullrich; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal.

Authors:  J I Macdonald; R J Herman; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.